What changes in the therapeutic management of papillary thyroid carcinoma. Emerging evidence.

The low mortality of papillary thyroid carcinoma (PTC) has led to progressively less aggressive therapeutic approaches according to the latest 2025 guidelines. However, morbidity associated with persistent disease and cervical lymph node metastases remains a significant clinical challenge. The presence of undetected "occult" metastases and the occurrence of nodal recurrences following apparently adequate treatment raise concerns regarding the effectiveness of current diagnostic and therapeutic strategies. Improving preoperative diagnostic accuracy in assessing both the extent and aggressiveness of the disease could play a decisive role in selecting the most appropriate surgical approach and the need for adjuvant radioactive iodine (RAI) therapy. Precise topographical localization of the tumor represents an additional risk factor that should be incorporated into therapeutic decision-making.